Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

NewsGuard 100/100 Score
Apr 29 2015

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency ("EMA") has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.

"Our submission to the EMA included survival data from our single arm gemcitabine/REOLYSIN® (REO 017) clinical study in pancreatic cancer patients, which factored into their decision to grant us the designation," said Dr. Brad Thompson, President and CEO of Oncolytics.

Source:

Oncolytics Biotech Inc.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels
New trials show promise for immune checkpoint blockers in early-stage lung cancer
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery
MONET: New AI tool enhances medical imaging with deep learning and text analysis
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis
Breakthrough imaging method enhances precision in prostate cancer treatment

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study links air pollution to increased colorectal cancer risk through DNA changes